Please login to the form below

Not currently logged in

Healthcare at Home and QED partner on orphan diseases

OrphanReach alliance will see companies provide product lifecycle services

Healthcare at Home and QED Clinical Services have formed a strategic alliance under the OrphanReach banner to support the launch of products for rare and orphan diseases.

Homecare and patient support company Healthcare at Home and QED Clinical Services, a clinical research organisation (CRO), said the alliance would serve a unique market with a unique proposition.

Mike Gordon, CEO for Healthcare at Home, said: “OrphanReach will solve some key problems facing biopharmaceutical companies launching new medicines. It will ensure that pre-launch plans are data rich, evidence based and patient focused. It will ensure that market access is optimised and product launches are as successful as can be.”

Services offered by the UK firm's new OrphanReach alliance will include clinical support and integrated patient management with an ambition to provide “the most integrated clinical development programme and launch plan within rare and orphan conditions”.

Healthcare at Home has 15 years' experience of working in rare and orphan diseases and has supported the launch of many products across Europe, where it has been tasked with services that include running homecare arms in clinical trials.

Meanwhile, global CRO QED was founded in 2002 and has worked on more than 70 rare disease projects.

Its CEO, Thomas Ogorka, said: “We are delighted to be working alongside Healthcare at Home in this strategic alliance. We have a rich track record of optimising clinical development within rare and orphan markets and this alliance enables QED to take the range of services we can offer to a new level but more importantly support clients in a far deeper and more strategic way.”

21st May 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...